Show simple item record

dc.contributor.authorHedenström, Per
dc.date.accessioned2018-03-01T13:31:18Z
dc.date.available2018-03-01T13:31:18Z
dc.date.issued2018-03-01
dc.identifier.isbn978-91-629-0400-5 (print)
dc.identifier.isbn978-91-629-0401-2 (pdf)
dc.identifier.urihttp://hdl.handle.net/2077/54540
dc.description.abstractBackground and aims: Endosonography-guided fine needle aspiration (EUS-FNA) is imperfect in diagnosing solid pancreatic lesions (SPL) and subepithelial lesions (SEL) including gastrointestinal stromal tumors (GIST). In GISTs, imatinib therapy is effective only in variants of oncogenes KIT and PDGFRA. The global aim was to improve the EUS-diagnostics and study a biopsy approach (EUS-FNB) to obtain a reliable diagnosis of SPLs and SELs. In GISTs, the aim was to evaluate pretreatment samples for tumor risk assessment and the guidance of down-sizing imatinib therapy. Methods: In two prospective, single-center studies (2012–2015), SPLs (n=68,Paper I) and SELs (n=70,Paper II) were sampled with EUS-FNA and EUS-FNB. A reference cohort (2006–2011) was used for comparison. The EUS-FNB-tissue of all GISTs (n=44) was subjected to Ki-67-indexing and DNA-sequencing of KIT and PDGFRA (Paper III). In a last study (Paper IV), pretreatment sequencing of GISTs (n=59) was performed. Results: Paper I: In SPLs, EUS-FNB and EUS-FNA had a comparable diagnostic accuracy (69% vs 78%, p=0.31). The combination EUS-FNA+FNB was superior to EUS-FNA alone in pancreatic non-adenocarcinoma neoplasms (89% vs 69%, p=0.02). Paper II: In SELs, EUS-FNB had a higher diagnostic accuracy compared with EUS-FNA (83% vs 49%, p<0.001) leading to the reduced need for additional diagnostic procedures (14% vs 53%, p<0.001). Paper III: The EUS-FNB-tissue was diagnostic for GIST in 98%, accurate for Ki-67-indexing in 92%, and adequate for successful sequencing in 98% of the cases. In patients treated with down-sizing imatinib [KIT exon 11 (n=9); PDGFRA exon 12 (n=1)], the Ki-67-index was significantly higher in pretreatment FNB-tissue compared with resection specimens: Ki-67DIFF = 2.3 (95% CI: 0.67-5.37, p=0.005). Paper IV: Pretreatment sequencing, compared with no sequencing, lead to a higher rate of accurate down-sizing therapy (97% vs 70 %, p<0.001) and to the increased preoperative tumor size reduction on CT scan (32% vs 22%, p=0.036). Conclusions: The performance of endosonography-guided fine-needle biopsy sampling has a significant diagnostic and clinical value in subepithelial lesions; especially in gastrointestinal stromal tumors. The acquired tissue is also accurate for the early tumor proliferation rate assessment and genetic profiling of GISTs. The suggested work-up approach facilitates the guidance and evaluation of down-sizing tyrosine kinase inhibitor therapy.sv
dc.language.isoengsv
dc.relation.haspartI. EUS-guided reverse bevel fine-needle biopsy sampling and open tip fine-needle aspiration in solid pancreatic lesions - a prospective, comparative study. Hedenström P, Demir A, Khodakaram K, Nilsson O, Sadik R. Scand J Gastroenterol. 2018 Feb;53(2):231-237. ::doi::10.1080/00365521.2017.1421704sv
dc.relation.haspartII. High clinical impact and diagnostic accuracy of EUS-guided biopsy sampling of subepithelial lesions: a prospective, comparative study. Hedenström P, Marschall HU, Nilsson B, Demir A, Lindkvist B, Nilsson O, Sadik R. Surg Endosc. 2018 Mar;32(3):1304-1313. ::doi::10.1007/s00464-017-5808-2sv
dc.relation.haspartIII. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies. Hedenström P, Nilsson B, Demir A, Andersson C, Enlund F, Nilsson O, Sadik R. World J Gastroenterol. 2017 Aug 28;23(32):5925-5935. ::doi::10.3748/wjg.v23.i32.5925sv
dc.relation.haspartIV. Pretreatment mutational analysis of KIT and PDGFRA optimizes down-sizing imatinib therapy of gastrointestinal stromal tumors Hedenström P, Andersson C, Sjövall H, Enlund F, Nilsson O, Nilsson B, Sadik R. Manuscriptsv
dc.subjectendosonographysv
dc.subjectfine-needle biopsysv
dc.subjectpancreatic neoplasmssv
dc.subjectgastrointestinal stromal tumorssv
dc.subjectKITsv
dc.subjectPDGFRAsv
dc.subjectKi-67sv
dc.subjectimatinibsv
dc.subjectneoadjuvant therapysv
dc.titleEndosonography and pretreatment tumor profiling - from sampling, staining, to sequencingsv
dc.typetexteng
dc.type.svepDoctoral thesiseng
dc.gup.mailper.hedenstrom@vgregion.sesv
dc.type.degreeDoctor of Philosophy (Medicine)sv
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academysv
dc.gup.departmentInst of Medicine. Department of Internal Medicine and Clinical Nutritionsv
dc.gup.defenceplaceFredagen den 23 mars 2018, klockan 13.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborgsv
dc.gup.defencedate2018-03-23
dc.gup.dissdb-fakultetSA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record